Eikon Therapeutics
Focus: Eikon Therapeutics is a clinical-stage biotech company leveraging single-particle tracking technology to develop oncology, ophthalmology, neurology, and gene therapy candidates. The company is publicly traded (NASDAQ: EIKN) with a focused pipeline in immuno-oncology and solid tumors.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Open Jobs
21-7 this month
Cooling — net -7 jobs in 30d
6 added, 13 removed. Slower than typical.
Should You Work at Eikon Therapeutics?
AI assessmentEikon presents a growth-stage opportunity with differentiated science, but recent layoffs and early-stage pipeline create meaningful execution risk for career stability.
Why Work Here
- Proprietary single-particle tracking platform provides differentiated technology foundation across multiple therapeutic areas (oncology, ophthalmology, neurology, gene therapy)
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
11 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
BDB001
Tumor, SolidClinical Trials (1)
NCT04196530BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
Phase 1Help build intelligence for Eikon Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.